Unshelved.bio finds promising drug candidates that have been quietly abandoned by their developers, and flags them to the rare disease foundations who can actually push them forward.
My dad never smoked a day in his life, but he still developed a rare form of lung cancer.
Rare disease isn't fair, and sometimes the drug development process isn't either. Foundations and patients rally behind potentially life-saving drugs only for them to be shelved due to business priorities and high-level strategy. It can be devastating, and it's more common than people think.
I'm working on Unshelved.bio to find these compounds and flag them to the foundations who can push them forward — for patients, not profit.
— Andre Pang, founder
We continuously scan clinical trial databases, pharma pipelines, and out-licensing portals for drug candidates that have been deprioritized, terminated for non-safety reasons, or quietly put on the shelf.
Most compounds that look shelved aren't actually available — they've been re-acquired, renamed, or are in active development elsewhere. We rule those out so the foundations don't have to.
The remaining candidates get matched to rare disease foundations whose patients could benefit — and whose leadership is in a position to take the next step, whether that's funding a trial, brokering a license, or finding the right development partner.
We're starting with a small number of foundations and a small number of high-conviction candidates. If you're a scientific director, board member, or program lead at a rare disease foundation, get in touch.
Reach out →Occasional updates — what we're finding, what's getting picked up, what's not. No pitches, no spam.